Binkow & Goldberg LLP announces that it is investigating
potential claims on behalf of shareholders of Aegerion
Pharmaceuticals, Inc. ("Aegerion" or the "Company") (NASDAQ:AEGR)
concerning possible violations of federal securities laws. The
investigation focuses on certain statements issued by Aegerion
concerning the Company's operations and financial performance and
PLEASE CONTACT US AT (212) 682-5340, TOLL-FREE AT (888) 773-9224, OR AT SHAREHOLDERS@GLANCYLAW.COM,TO
DISCUSS THIS MATTER OR OTHER POTENTIAL CLAIMS IF YOU ARE A LONG-TERM
SHAREHOLDER OF AEGERION. IF YOU INQUIRE BY EMAIL PLEASE INCLUDE YOUR
MAILING ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES PURCHASED.
Aegerion markets its cholesterol drug Juxtapid in the United States.
Juxtapid is the sole FDA-approved Aegerion product. Jxtapid was
approved by U.S. health regulators in December 2012 to treat patients
with homozygous familial hypercholesterolemia (HoFH), a rare genetic
disease that impairs the function of the receptor responsible for
removing LDL-C or "bad" cholesterol from the blood.
The investigation is related to the Company's January 9, 2014,
announcement that the Company received a subpoena from the U.S.
Department of Justice requesting documents on its marketing and sale of
Juxtapid. Reportedly, Chief Executive Officer Marc Beer received a
warning letter from the Food and Drug Administration in November about
comments in an interview on CNBC. According to sources, the FDA said
Beer's statements "provide evidence that Juxtapid is intended for new
uses, for which it lacks approval and for which its labeling does not
provide adequate directions for use." The Company reportedly is also
reducing its previously announced projections for FY 2014. Aegerion
dropped as much as 16 percent to $61.00 in response during extended
If you purchased Aegerion common stock between April 30, 2013 and
January 9, 2014, if you have information or would like to learn more
about these claims, or if you are a long-term shareholder of Aegerion
and have any questions concerning this announcement or your rights or
interests with respect to these matters, please contact Michael
Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century
Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888)
773-9224, or contact Gregory
Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd
Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by
e-mail to email@example.com,
or visit our website at http://www.glancylaw.com.
If you inquire by email, please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
[ Back To NFVZone's Homepage ]